Prospective Grant of a Co-Exclusive License: Adenovirus-Based Controls and Calibrators for Molecular Diagnostics of Infectious Disease Agents, 3906 [2013-00878]

Download as PDF pmangrum on DSK3VPTVN1PROD with 3906 Federal Register / Vol. 78, No. 12 / Thursday, January 17, 2013 / Notices Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6208, MSC 7804, Bethesda, MD 20892, (301) 435– 2477, zargerma@csr.nih.gov. Name of Committee: Population Sciences and Epidemiology Integrated Review Group; Neurological, Aging and Musculoskeletal Epidemiology Study Section. Date: February 14–15, 2013. Time: 8:30 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Crowne Plaza Riverwalk, 111 East Pecan Street, San Antonio, TX 20892. Contact Person: Heidi B Friedman, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1012A, MSC 7770, Bethesda, MD 20892, 301–435– 1721, hfriedman@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Topics in Infectious Diseases and Microbiology. Date: February 14–15, 2013. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting). Contact Person: Liangbiao Zheng, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3202, MSC 7808, Bethesda, MD 20892 301–996– 5819, zhengli@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Basic Biology of Neurological Disorders. Date: February 14, 2013. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Laurent Taupenot, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4811, MSC 7850, Bethesda, MD 20892, 301–435– 1203, taupenol@csr.nih.gov. Name of Committee: Cardiovascular and Respiratory Sciences Integrated Review Group; Electrical Signaling, Ion Transport, and Arrhythmias Study Section. Date: February 15, 2013. Time: 8:00 a.m. to 6:30 p.m. Agenda: To review and evaluate grant applications. Place: Marina Del Rey Hotel, 13534 Bali Way, Marina Del Rey, CA 90292. Contact Person: Yuanna Cheng, MD, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4138, MSC 7814, Bethesda, MD 20892, (301) 435– 1195, Chengy5@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; RFA Panel: Molecular Probes. Date: February 15, 2013. Time: 10:00 a.m. to 5:00 p.m. VerDate Mar<15>2010 14:19 Jan 16, 2013 Jkt 229001 Agenda: To review and evaluate grant applications. Place: Pier 5 Hotel, 711 Eastern Avenue, Baltimore, MD 21202. Contact Person: Mary Custer, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4148, MSC 7850, Bethesda, MD 20892, (301) 435– 1164, custerm@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cell Biology. Date: February 15, 2013. Time: 11:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Raya Mandler, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5217, MSC 7840, Bethesda, MD 20892, 301–402– 8228, rayam@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: January 11, 2013. Anna Snouffer, Deputy Director, Office of Federal Advisory Committee Policy. [FR Doc. 2013–00882 Filed 1–16–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of a Co-Exclusive License: Adenovirus-Based Controls and Calibrators for Molecular Diagnostics of Infectious Disease Agents National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of a worldwide co-exclusive license, to practice the inventions embodied in US patent 6,013,638 (HHS Reference# E–129– 1991/0–US–03), issued January 11, 2000 and entitled ‘‘Adenovirus Comprising Deletions on the E1A, E1B And E3 Regions for Transfer of Genes to the Lung’’, and US patent 6,136,594 (HHS Reference# E–129–1991/1–US–03), issued October 24, 2000, and entitled ‘‘Replication Deficient Recombinant SUMMARY: PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 Adenovirus Vector’’ to Life Technologies Corporation (LTC) of Carlsbad, California. The United States of America is an assignee of the rights of the above inventions. The field of use may be limited to the ‘‘use of adenovirus-based recombinant constructs as controls and calibrators for molecular diagnostics for infectious disease agents.’’ DATES: Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before February 19, 2013 will be considered. ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Uri Reichman, Ph.D., M.B.A, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435– 4616; Facsimile: (301) 402–0220; Email: Reichmau@mail.nih.gov. SUPPLEMENTARY INFORMATION: The invention relates to recombinant adenovirus vectors containing foreign DNA. Such vectors can be used for gene transfer, therapeutics, and protein expression. The technology can also be utilized to make calibrators and controls for molecular diagnostics (e.g. real time PCR tests). The prospective co-exclusive license will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective co-exclusive license may be granted unless, within thirty (30) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Dated: January 11, 2013. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2013–00878 Filed 1–16–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY Coast Guard [USCG–2012–1096] Information Collection Request to Office of Management and Budget Coast Guard, DHS. Sixty-day notice requesting comments. AGENCY: ACTION: E:\FR\FM\17JAN1.SGM 17JAN1

Agencies

[Federal Register Volume 78, Number 12 (Thursday, January 17, 2013)]
[Notices]
[Page 3906]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-00878]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of a Co-Exclusive License: Adenovirus-Based 
Controls and Calibrators for Molecular Diagnostics of Infectious 
Disease Agents

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services (HHS), is contemplating the 
grant of a worldwide co-exclusive license, to practice the inventions 
embodied in US patent 6,013,638 (HHS Reference E-129-1991/0-
US-03), issued January 11, 2000 and entitled ``Adenovirus Comprising 
Deletions on the E1A, E1B And E3 Regions for Transfer of Genes to the 
Lung'', and US patent 6,136,594 (HHS Reference E-129-1991/1-
US-03), issued October 24, 2000, and entitled ``Replication Deficient 
Recombinant Adenovirus Vector'' to Life Technologies Corporation (LTC) 
of Carlsbad, California. The United States of America is an assignee of 
the rights of the above inventions.
    The field of use may be limited to the ``use of adenovirus-based 
recombinant constructs as controls and calibrators for molecular 
diagnostics for infectious disease agents.''

DATES: Only written comments and/or applications for a license received 
by the NIH Office of Technology Transfer on or before February 19, 2013 
will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Uri Reichman, Ph.D., M.B.A, Office of Technology 
Transfer, National Institutes of Health, 6011 Executive Boulevard, 
Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-4616; 
Facsimile: (301) 402-0220; Email: Reichmau@mail.nih.gov.

SUPPLEMENTARY INFORMATION: The invention relates to recombinant 
adenovirus vectors containing foreign DNA. Such vectors can be used for 
gene transfer, therapeutics, and protein expression. The technology can 
also be utilized to make calibrators and controls for molecular 
diagnostics (e.g. real time PCR tests).
    The prospective co-exclusive license will comply with the terms and 
conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective co-
exclusive license may be granted unless, within thirty (30) days from 
the date of this published notice, NIH receives written evidence and 
argument that establishes that the grant of the license would not be 
consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

    Dated: January 11, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-00878 Filed 1-16-13; 8:45 am]
BILLING CODE 4140-01-P